Kala Bio KALA
NASDAQ KALA
$0.16 +0.01 (+4.36%)
As of: Nov 9, 2026 · 10:11 AM EST

Kala Bio (KALA) Gains from Sales and Divestitures (2018 - 2022)

Updated

Analysis

Kala Bio (KALA) Gains from Sales and Divestitures (2018 - 2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,243.39 Bn 1,217.00 Bn 20.46 Bn
2 Johnson & Johnson 667.00 Bn 586.86 Bn 17.30 Bn
3 AbbVie 513.50 Bn 481.51 Bn 13.12 Bn
4 Merck 362.97 Bn 325.91 Bn 13.19 Bn
5 Novartis Ag 314.03 Bn 287.27 Bn -
6 Astrazeneca 291.59 Bn 265.49 Bn 13.26 Bn
7 Amgen 247.24 Bn 198.89 Bn 7.58 Bn
8 Gilead Sciences 208.09 Bn 183.20 Bn 6.73 Bn
9 Pfizer 166.41 Bn 113.77 Bn 12.56 Bn
10 Kala Bio 2.52 Mn -42.12 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2022 47.00 Mn
Sep 30, 2018 -5,000.00
Mar 31, 2018 -4,000.00
API Access

Kala Bio Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=KALA&period=max&api_key=YOUR_API_KEY